U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06857240) titled 'Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis' on Feb. 26.
Brief Summary: This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. Our hypothesis is that topical ruxolitinib will be both safe and effective for such patients.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Dermatomyositis
Intervention:
DRUG: Ruxolitinib Topical Cream
1.5% cream
Recruitment Status: NOT_YET_RECRUITING
Sponsor: The Cleveland Clinic
Information provided by (Responsible Party): Anthony Fernandez, MD, PhD, T...